INS and diabetes mellitus: Treatment with vildagliptin 50–100 mg daily in patients with type 2 diabetes mellitus (T2DM) significantly improved markers of beta cell function including homeostasis model assessment-ß (HOMA-3), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test [27–29].